New Research Identifies Cells Targeted by Autoimmune Effects of IPEX Syndrome
jarmoluk / Pixabay

New Research Identifies Cells Targeted by Autoimmune Effects of IPEX Syndrome

According to a publication from Karolinska Institutet, a medical research university near Stockholm, Sweden, new research led by the University suggests that regulatory T cells have an especially important role…

Continue Reading New Research Identifies Cells Targeted by Autoimmune Effects of IPEX Syndrome

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug
Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run
https://pixabay.com/en/technology-robot-human-hand-2025795/

Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run

According to an article from CW associate WBCB, Dutch startup Nori Health has started open enrollment in the six-week test of its eponymous experimental chatbot, Nori. Nori aims to help…

Continue Reading Inflammatory Bowel Disease Patient Wellness Chatbot Starts 6-Week Test Run
More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III
kkolosov / Pixabay

More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

According to a press release from the American Academy of Neurology published by EurekAlert, new research published in Neurology further suggests that established spinal muscular atrophy (SMA) drug nusinersen could…

Continue Reading More Evidence Suggesting Nusinersen Effective for Spinal Muscular Atrophy Types II and III

FDA Grants Orphan Drug Designation to Experimental Acute Lymphoblastic Leukemia Drug

According to a press release from British biopharmaceutical manufacturer Autolus Therapeutics, the American Food and Drug Administration (FDA) has granted the Company's experimental acute lymphoblastic leukemia (ALL) cell-based immunotherapy treatment…

Continue Reading FDA Grants Orphan Drug Designation to Experimental Acute Lymphoblastic Leukemia Drug

Edible Antibodies Halt E. Coli in Pigs, Could Help End Overuse of Antibiotics

According to a publication at BioPortfolio, Belgian researchers are developing an orally-administered antibody medication for patients living with gastrointestinal disorders. In most cases, antibodies are injected into the bloodstream for…

Continue Reading Edible Antibodies Halt E. Coli in Pigs, Could Help End Overuse of Antibiotics
Muscular Dystrophy Association to Host First Annual Combined Conference
Hundreds of people living with narcolepsy gathered at the NN's 2015 Conference to make friends and learn something new. Source: Narcolepsy Network

Muscular Dystrophy Association to Host First Annual Combined Conference

A recent publication from Charcot-Marie-Tooth News announced that this year, for the first time ever, the Muscular Dystrophy Association will be hosting its annual clinical conferences at the same event…

Continue Reading Muscular Dystrophy Association to Host First Annual Combined Conference
AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms
jarmoluk / Pixabay

AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms

A press release from American biopharmaceutical company AMO Pharma, published by PR Newswire, detailed the recent completion of the Company's new congenital myotonic dystrophy type 1 (CDM1) symptom-evaluation scale. The…

Continue Reading AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms
Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis
Source: Pixabay.com

Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis

According to a press release from American biotechnology company Intercept Pharmaceuticals, the company recently released additional data supporting its phase 3 clinical trial of obeticholic acid (OCA) in the treatment…

Continue Reading Phase 3 Study Data Shows Obeticholic Acid Could Treat NASH-Linked Fibrosis

Experimental Drug for HPV-Linked Recurrent Respiratory Papillomatosis Shows Early Promise

According to a press release from Inovio Pharmaceuticals, the American biotech company's experimental recurrent respiratory papillomatosis (RRP) drug INO-3106 showed promising results at the end of a pilot clinical study…

Continue Reading Experimental Drug for HPV-Linked Recurrent Respiratory Papillomatosis Shows Early Promise
Despite New Inflammatory Bowel Disease Therapies, Difficulty Treating Persists
source: pixabay.com

Despite New Inflammatory Bowel Disease Therapies, Difficulty Treating Persists

In a recent video interview with Healio, Dr. David Rubin recapped some of his discussion at the 2019 Interdisciplinary Autoimmune Summit. At the summit, he and his colleagues spoke about…

Continue Reading Despite New Inflammatory Bowel Disease Therapies, Difficulty Treating Persists